Hillcrest Energy Technologies

LATEST MEDICINAL CANNABIS STOCK NEWS


SciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million

Wellution™ offers dozens of products including natural supplements, creams, gels and hemp-based products on Amazon.com Marketplace SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the closing of the definitive agreements for its acquisition of... Read more


Entourage Health Launches Unique Medical Cannabis Marketplace “Syndicate” Offering Premium Craft Products From Collective of In-House and Third-Party Micro...

Syndicate marketplace showcases a variety of specially curated products and formats made in-house and/or sourced from micro-cultivators looking for a medical distribution outlet As a supplemental market to insured benefits channel Starseed Medicinal, Syndicate will offer clients sans insurance access a variety of brand favourites including Color & Saturday Cannabis Entourage Health Corp. (TSX-V:ENTG)... Read more


Akanda Plans First Shipment of Medical Cannabis to Germany and Anticipates Leading Market Share Position

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) expects to take a leading position in the fast-growing German medical cannabis market, as it prepares for first export shipment from its Portugal-based Holigen operation in the coming weeks. Akanda’s EU GMP certified indoor grow facility in Sintra received its first purchase order and is expected to make its... Read more


Tilray Medical Receives Approval to Extend Market Authorization in Italy

Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, today announced that FL Group S.R.L. (“FL Group”), a division of Tilray Medical in Italy, has received approval from the Italian Ministry of Health to import and distribute Tilray’s medical cannabis oral solution THC25... Read more


SciSparc and Clearmind Medicine Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0), has filed a provisional patent application related to metabolic syndromes including obesity, regarding the... Read more


Trulieve Cannabis Wins Georgia Production License to Provide Patients Access Statewide to Medical Cannabis

Company expands Southeast Hub with Class 1 license in Georgia Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the Georgia Access to Medical Cannabis Commission ("GMCC" or "Commission") awarded Trulieve GA, Inc. with a Class 1 production license. Trulieve patients in Georgia will be able to choose... Read more


Innocan Pharma Provides an Operational Update

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, is pleased to provide the following operational update on its key lines of business: Recent development: We are happy to announce that the PCT title as " CANNABIDIOL-CONTAINING... Read more


Skye Bioscience Completes Drug Production for Phase 1 Clinical Study

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer (“CMO”) that it has completed the production of SBI-100 Ophthalmic Emulsion (“SBI-100 OE”) for Skye’s Phase 1 clinical trial. The final drug product will be released and available for... Read more


Curaleaf Completes Majority Stake Acquisition of Germany's Four 20 Pharma

Deal Solidifies Curaleaf's Strategic Advantage in Germany as the Country Prepares for Adult-Use Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced the completion of its agreement to acquire a 55% stake in Four 20 Pharma GmbH, a fully EU-GMP & GDP licensed German producer and distributor of... Read more


PharmaCielo Announces Shipment of Dried Cannabis Flower to the Czech Republic, Representing the Company's First Shipment of Medicinal Grade Dried Cannabis...

Shipment made to an established pharmaceutical distributor and clinical research organization in the Czech Republic, focused on medicinal grade cannabinoids PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"),... Read more


Lifeist Wellness Mikra Increases Active Subscriptions, is Set to Launch CELLF v1.2, and Expands Marketing and Product Initiatives

Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. (“Mikra”) has increased its active monthly subscriber count by 173% in Q3 2022... Read more


Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto

Dr. Mac Burnham’s team will explore Avicanna’s drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures. Avicanna further expands its current research and commercial focus in Epilepsy which is supported by current medical cannabis sales and on-going research with UHN Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a... Read more


PharmaCielo Announces Receipt of Production Quota of THC Dominant Dried Cannabis Flower for Export - Commercial Quantities of Flower Shipments to Begin in Early...

Colombian government has maintained its commitment to supporting its cannabis producers and building a dominant global export industry. Five tonne quota to grow THC-dominant cannabis strains for export as dried flower will support the fulfillment of current sales agreements, beginning in early 2023. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO)... Read more


Akanda Partners with Cookies to Bring the Iconic Cannabis Brand and High THC Strains to European Consumers for the First Time

International medical cannabis platform company Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN) today announced an exclusive license agreement with iconic international cannabis lifestyle brand Cookies. The multi-year agreement enables Akanda to pursue the current medical and future adult-use opportunities in Europe with arguably one of the best-known cannabis brands and highest quality genetics in the... Read more


Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment

A 4-year-old intact male border collie dog with a body weight of 22 kg was suffering from refractory idiopathic (drug-resistant) epilepsy The dog was frequently hospitalized to stop seizure clusters Following treatment using Innocan's LPT (CBD Loaded Liposome Platform), seizures stopped for 9.5 weeks Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to... Read more


Canopy Growth: Storz & Bickel Debuts "with Love, for Peace" Limited-Edition VOLCANO CLASSIC

A portion of every Peace edition produced will be donated to charitable organizations that help those in need STORZ & BICKEL GmbH ("STORZ & BICKEL"), a world-leading manufacturer of high-end and medically certified cannabis vaporizers and subsidiary of Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC), today unveiled a limited-edition version of its flagship VOLCANO CLASSIC device: the PEACE VOLCANO.... Read more


Medical Marijuana Signs Deal With Leading European Manufacturer and Distributor to Expand Channel Access to Products Throughout the Region

Global Cannabis Company Expands Supply Chain in Europe through Agreement with Complete Hemp Technologies Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary, Kannaway, has signed a distribution... Read more


Tetra Bio-Pharma Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that the Company has revised the terms of its previously announced financing arrangement (the "Financing") with Global Corporate Finance Opportunities 16 (the "Investor"), an investment vehicle advised by Alpha Blue Ocean ("ABO"), and has... Read more


Tilray Initiates Roundtable With German Regulators to Kick-Off Draft Legislation to Legalize Adult-Use Cannabis in Germany

Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company, today announced that the Company has initiated a policy roundtable with German regulators on adult-use cannabis legalization in Germany. In this meeting, the German Drug Commissioner, Burkhard Blienert, presented the plan for adult-use cannabis legalization and repeated the... Read more


Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, describes their progress towards achieving significant milestones in their drug development pipeline in an article published in the journal Pharma's Almanac today at... Read more


Appointment of Sachin Nanavati to PreveCeutical Medical Board of Directors

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the appointment of Mr. Sachin Nanavati to the Company's board of directors (the "Board") effective September 1, 2022. Sachin is currently the Head of Industry, Healthcare with Google, Inc. He has vast knowledge and experience with healthcare and technology. Sachin was a founding member of Meta... Read more


Love Hemp Launches Products in Tesco Supermarkets

Love Hemp Group PLC ("Love Hemp", the "Group", or the "Company") (AQSE:LIFE)(OTCQB:WRHLF), the brand-led consumer goods company focussed on CBD health and wellness solutions, is pleased to announce that TESCO PLC, ("Tesco"), is now stocking Love Hemp CBD products. Tesco will initially stock a range of six Love Hemp products across more than 200 Tesco stores including "Tesco Extra" in the UK. Tesco Extra stores are... Read more


Khiron Life Sciences, the Global Leader in Medical Cannabis Launches New Cannabis Products in Europe including Stellar Genetics from California

New products to be distributed through Khiron's new wholly-owned subsidiary Pharmadrug Production GmbH Khiron introduces new THC-dominant full-spectrum extract KHIRIOX 25/1, and non-irradiated flower varieties KHIRON Gelato 19/1 and KHIRON Caramel 5/7 in the European market Khiron's expanded medical product portfolio in Europe will provide a broader patient base with in-demand products Khiron Life Sciences... Read more


Isracann Biosciences: Praesidio signs distribution agreement with Pure Integrative Pharmacy

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and holdings in Israel, is please to announce that it has signed a distribution agreement for Praesidio Health (Praesidio) products with Pure Integrative Pharmacy (PURE). “I am excited to announce our first executed... Read more


Entourage Health Signs Four New Union Groups to its Starseed Medicinal Program

Entourage Health Corp. (TSX-V:ENTG) (OTCQX:ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products, is pleased to announce its medical subsidiary Starseed Medicinal (“Starseed”) has added four new union groups to its full-service, proprietary medical cannabis program, in partnership with leading benefits provider Union Benefits – the... Read more


Innocan Pharma Announces Q2 2022 Results with 70% Annual Increase in Cash Balance and 70% Increase in Working Capital

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to report its financial results for the quarter ended June 30, 2022. Second Quarter 2022 Financial and Operating Highlights (unaudited): Cash balance at end of Q2-22 - USD 7.7M, in Q2-21 - USD 4.6M, an increase of approximately of 70% from the corresponding quarter. Revenues in Q2-22 - USD 415 thousand... Read more


Cansortium Reports Second Quarter 2022 Financial Results

Q2 Revenue up 14% QoQ and 36% YoY to a Record $22.4 Million  Q2 Adjusted EBITDA up 64% QoQ and 95% YoY to a Record $10.2 Million, with $4.3 Million of Cash from Operations  Reaffirms 2022 Guidance of $90-$95 Million of Revenue and $25-$28 Million of Adjusted EBITDA  Cansortium Inc. (CSE:TIUM.U) (OTCQX: CNTMF) ("Cansortium" or the "Company"), a vertically-integrated cannabis company operating... Read more


Khiron Life Sciences Reports Second Quarter 2022 Financial Results

Reports revenues of $9.1 million in the first half of 2022, up 62% year-over-year, reflecting continued medical cannabis momentum in target markets Recorded its lowest ever Adjusted EBITDA loss in Q2 2022 at ($2.3) million, down 30% quarter-over-quarter and 39% year-over-year Net loss of ($2.2) million for Q2 2022 represents a 60% decrease quarter-over-quarter and 55% year-over-year Net cash used in operating... Read more


Tilray Launches New Products and ‘CannaPoints’ Program to Support Patients Across Canada

Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company, today announced that its medical cannabis division, Tilray Medical, has released new medical cannabis products, under Tilray and Aphria brands and launched CannaPoints, a new program designed to support patients through their medical cannabis journey. Blair MacNeil, President,... Read more


Skye Bioscience Reports that Emerald Health Therapeutics Shareholders Voted in Favor of Plan of Arrangement with Skye

San Diego, California, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the shareholders of Emerald Health Therapeutics, Inc. ("Emerald" or the "Company") (CSE: EMH; OTCQB: EMHTF) today approved the proposed plan of arrangement (the... Read more


IM Cannabis Announces USD$5,000,000 Private Placement Led by Management

IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, is pleased to announce that it is undertaking a non-brokered private placement for aggregate gross proceeds of up to USD$5,000,000 (the "Offering"). The Offering, which is expected to close in one or more tranches, will be led by... Read more


Tilray Medical Bolsters Market Leading Position in Europe With Market Authorization in Poland

Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that its medical cannabis division, Tilray Medical, has received approval to commercialize its Tilray branded medical cannabis products in Poland expanding its product offering... Read more


AREV Nanotec Brands Corporate Update

AREV LIFE SCIENCES GLOBAL CORP. (CSE:AREV) (OTC:AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporation announces a corporate update on progress of its business streams.    Arev, like many other companies, has felt the impact of the lock downs and changes in market conditions as a result of Covid-19, the war in Ukraine and now global inflation. We believe AREV is very well... Read more


Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

6 dogs suffering from osteoarthritis and lameness demonstrated CBD concentrations 6 weeks after a single injection Pain and well-being scores improved following treatment Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce positive partial results in a pilot pain study in dogs using the LPT CBD Liposomal Delivery Platform. Six dogs... Read more


SciSparc Signs a Non- Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million Deal

The Letter of Intent contemplates the purchasing of a brand, trademark and Amazon.com seller account, a management agreement, a U.S. distribution agreement and an option to expand to new territories TEL AVIV, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies... Read more


MediPharm Labs Reports Second Quarter Results

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and six months ended June 30, 2022. Q2 2022 – Select Recent Operating Highlights Streamlining and Focusing Operations On April 20th, experienced Pharma and Med Tech executive David... Read more


CV Sciences Announces Launch of PlusCBD™ Reserve Collection Softgels

PlusCBD™'s latest product leverages CBD and THC to target anxiety and stress CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced the launch of +PlusCBD™Reserve Collection Softgels to support stress relief and relaxation. The... Read more


Emerald Health Therapeutics Provides Update on and Additional Background to Transaction with Skye Bioscience

Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing an update and additional background on its transaction (the "Transaction") with Skye Bioscience Inc. (OTCQB: SKYE) ("Skye") pursuant to the terms of an arrangement agreement dated May 11, 2022, as amended (the "Arrangement Agreement"). On July 28, 2022, Emerald mailed to shareholders of Emerald (the "EHT... Read more


Leafly Holdings Reports Second Quarter 2022 Financial Results

Leafly Holdings, Inc. (“Leafly” or “the Company”) (NASDAQ: LFLY), a leading online cannabis discovery marketplace and resource for cannabis consumers, today announced financial results for its second quarter ended June 30, 2022. “Revenue in the quarter was $12.1 million, up 13.8% over Q2 last year, and up 5.5% over Q1 as we continue to build on the investments we’ve made in the first half of this year.... Read more


Aleafia Health Announces $12.0 Million Total Net Revenue in First Quarter, Representing a 13% Increase Over the Prior Year

31% increase in branded cannabis net revenue1 to $10.0 million from $7.6 million in the prior year #12 ranking for market share in core markets2 for Q1 FY2023 In the Ontario value category, Divvy has attained #5 market share in pre-roll and #7 in flower Secured new international partnership representing approximately $4.6 million sales commitment 12% increase in medical cannabis net revenue3 over the prior... Read more

COPYRIGHT ©2022 GREEN STOCK NEWS